Regadenoson
- Generic Name
- Regadenoson
- Brand Names
- Lexiscan, Rapiscan
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18N8O5
- CAS Number
- 313348-27-5
- Unique Ingredient Identifier
- 7AXV542LZ4
- Background
Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.
- Indication
Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)
Indies Pharma Secures FDA Approval for Generic Regadenoson, Targeting $400M Market
• Indies Pharma Jamaica has received FDA approval for its generic drug, Regadenoson, marking a historic milestone as the first Jamaican company to achieve this feat.
• The approval unlocks access to a substantial US$400 million market, positioning Indies Pharma among the top players in the United States for this medication.
• Generic Regadenoson is bioequivalent to Astellas Pharma's Lexiscan, offering a cost-effective alternative for patients undergoing cardiac stress tests.
• Indies Pharma anticipates significant revenue growth, projecting a potential doubling of sales and aiming for $2-3 billion in revenue by FY2025.
Astellas Faces Setback as US Court Invalidates Key Myrbetriq Patent
• A Delaware district court has invalidated Astellas' key patent for Myrbetriq (mirabegron), their blockbuster overactive bladder medication that generated $1.35 billion in revenue last fiscal year.
• Multiple generic versions of mirabegron have received approval, including from Zydus Cadila and Lupin Labs, though immediate launches are unlikely due to Astellas' planned appeal.
• The patent invalidation adds to Astellas' upcoming revenue challenges, including recent Lexiscan generic competition and the anticipated 2027 US patent expiration of their top-selling drug Xtandi.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath